近日，中国医学科学院Donglai Wang及其研究组撰写了综述文章——SET的下一个十年：从一个肿瘤蛋白到更多。相关论文于2023年12月29日在线发表在《分子细胞生物学报》上。

研究人员表示，今年是对1992年发现的SET蛋白进行研究的第四个十年。SET最初被确定为一种肿瘤蛋白，但后来被证明是一种多方面的蛋白，在生理和病理生理条件下参与调节许多生物过程。SET功能障碍与癌症和阿尔茨海默病等疾病密切相关。

随着人们对SET的工作原理及其在细胞中的调控方式的了解不断加深，靶向异常SET已成为一种潜在的疾病干预策略。

研究人员全面概述了SET研究的进展，包括其生物功能、调控网络、临床影响和药理抑制剂。此外，研究人员还深入探讨了SET研究的未来前景，并特别强调了其在免疫调节领域的巨大潜力。

附：英文原文

Title: The next decade of SET: from an oncoprotein to beyond

Author: Yao, Han, Zhang, Meng, Wang, Donglai

Issue&Volume: 2023-12-29

Abstract: This year marks the fourth decade of research into the protein SET, which was discovered in 1992. SET was initially identified as an oncoprotein, but later, it was shown to be a multifaceted protein involved in regulating numerous biological processes under both physiological and pathophysiological conditions. SET dysfunction is closely associated with diseases, such as cancer and Alzheimer's disease. With the increasing understanding of how SET works and how it is regulated in cells, targeting aberrant SET has emerged as a potential strategy for disease intervention. In this review, we present a comprehensive overview of the advancements in SET studies, encompassing its biological functions, regulatory networks, clinical implications, and pharmacological inhibitors. Furthermore, we provide insights into the future prospects of SET research, with a particular emphasis on its promising potential in the realm of immune modulation.

DOI: 10.1093/jmcb/mjad082

Source: https://dx.doi.org/10.1093/jmcb/mjad082